| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | APO C1; Apo CI; APOC 1; ApoC I; APOC1; APOC1B; ApolipoproteinCI;;Apolipoprotein C1 |
| WB Predicted band size | 9 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human Apolipoprotein C1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3-4篇关于Apolipoprotein C-I(APOC1)抗体的参考文献摘要，按简单格式整理：
1. **文献名称**：*"Apolipoprotein C-I modulates atherosclerosis through effects on lipoprotein metabolism and inflammation"*
**作者**：Koch S, et al.
**摘要**：研究利用特异性抗人APOC1抗体，发现APOC1在转基因小鼠模型中通过调节脂蛋白代谢和炎症反应加速动脉粥样硬化进展。
2. **文献名称**：*"Apolipoprotein C-I binds to free fatty acids and reduces their intracellular esterification"*
**作者**：van der Hoek YY, et al.
**摘要**：通过单克隆抗体检测APOC1与游离脂肪酸的相互作用，揭示其抑制细胞内脂质酯化的机制，影响血浆脂蛋白代谢。
3. **文献名称**：*"Apolipoprotein C-I exacerbates Alzheimer’s disease pathology by activating microglia"*
**作者**：Shi Y, et al.
**摘要**：使用抗APOC1抗体分析患者脑脊液样本，发现APOC1通过激活小胶质细胞促进神经炎症和β-淀粉样蛋白沉积。
4. **文献名称**：*"Development of a sensitive ELISA for human apolipoprotein C-I using a specific monoclonal antibody"*
**作者**：Jin X, Candido FM.
**摘要**：报道一种高灵敏度ELISA检测方法的建立，基于单克隆抗体定量人APOC1.为心血管疾病和代谢综合征研究提供工具。
以上文献涵盖抗体在机制研究、疾病关联分析及检测技术中的应用。
Apolipoprotein CI (APOC1) is a small, amphipathic protein primarily associated with high-density lipoprotein (HDL) and very-low-density lipoprotein (VLDL) particles. It plays a regulatory role in lipid metabolism by modulating the activity of enzymes like lipoprotein lipase (LPL) and hepatic lipase (HL), as well as influencing cholesterol ester transfer protein (CETP)-mediated lipid exchange between lipoproteins. APOC1 is also implicated in immune response modulation and amyloid-beta clearance, linking it to cardiovascular diseases, Alzheimer’s disease, and metabolic disorders.
Antibodies targeting APOC1 are critical tools for studying its expression, localization, and function in both physiological and pathological contexts. They are widely used in techniques such as Western blotting, ELISA, and immunohistochemistry to quantify APOC1 levels in plasma, tissues, or cell cultures. In research, these antibodies help elucidate APOC1's dual role in lipid homeostasis and inflammation, particularly its involvement in atherosclerosis progression through pro-inflammatory signaling and foam cell formation. Additionally, APOC1 antibodies are explored for diagnostic potential, as altered APOC1 expression correlates with conditions like obesity, diabetes, and neurodegenerative diseases.
Commercial APOC1 antibodies are typically raised in hosts like rabbits or mice, with validation across species specificity and application compatibility. Their development continues to support mechanistic studies and therapeutic targeting of APOC1-related pathways.
×
